Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated ...

脑转移（Brain Metastasis，BM）是非小细胞肺癌（Non-Small Cell Lung ...

Innovent Biologics (HKEX: 01801) has formed a strategic partnership with ASK Pharm (SZ: 002755) to commercialize limertinib, ...

Lazcluze demonstrated significant CNS activity, regardless of T790M status, in treating intracranial and leptomeningeal ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present a poster at the ...

The partners are preparing for commercialization of the lung cancer drug limertinib as they await an approval decision from China’s National Drug Administration.

Preliminary results for BDTX-1535 in NSCLC patients are expected in early 2025. Read more about Black Diamond Therapeutics ...

AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...

Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid ...

Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...

The firm is focusing its resources on developing its lead candidate, the EGFR inhibitor BDTX-1535, which is undergoing testing in EGFR-mutated NSCLC.